Literature DB >> 11095247

Src homology 2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase.

J A Rogers1, H Y Cheng, T E Smithgall.   

Abstract

The c-fes proto-oncogene encodes a Mr 93,000 protein-tyrosine kinase (Fes) that is strongly expressed in myeloid cells and has been implicated in myelomonocytic differentiation. Fes autophosphorylation and transforming activity are highly restrained after ectopic expression in fibroblasts, indicating tight negative regulation of Fes kinase activity in vivo. Here we investigated the regulatory role of the Fes Src homology 2 (SH2) domain by producing a series of chimeric constructs in which the Fes SH2 domain was replaced with those of the transforming oncogenes v-Fps and v-Src or by the NH2-terminal SH2 domain of the Ras GTPase-activating protein. Wild-type and chimeric Fes proteins readily underwent tyrosine autophosphorylation in vitro and produced identical cyanogen bromide phosphopeptide cleavage patterns, indicating that the SH2 substitutions did not influence overall kinase activity or autophosphorylation site selection. However, metabolic labeling of Rat-2 fibroblasts expressing each construct showed that only the Fes/Src SH2 chimera was active in vivo. Consistent with this result, the Fes/Src SH2 domain chimera exhibited potent transforming activity in fibroblasts and enhanced differentiation-inducing activity in K-562 myeloid leukemia cells. In addition, the Fes/Src SH2 chimera exhibited constitutive localization to focal adhesions in Rat-2 fibroblasts and induced the attachment and spreading of TF-1 myeloid cells. These data demonstrate a central role for the SH2 domain in the regulation of Fes kinase activity and biological function in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095247

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  7 in total

1.  The human c-Fes tyrosine kinase binds tubulin and microtubules through separate domains and promotes microtubule assembly.

Authors:  Charles E Laurent; Frank J Delfino; Haiyun Y Cheng; Thomas E Smithgall
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

2.  Solution structure of the Src homology 2 domain from the human feline sarcoma oncogene Fes.

Authors:  Anna Scott; David Pantoja-Uceda; Seizo Koshiba; Makoto Inoue; Takanori Kigawa; Takaho Terada; Mikako Shirouzu; Akiko Tanaka; Sumio Sugano; Shigeyuki Yokoyama; Peter Güntert
Journal:  J Biomol NMR       Date:  2005-04       Impact factor: 2.835

3.  Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.

Authors:  Jonathan M Shaffer; Thomas E Smithgall
Journal:  Genes Chromosomes Cancer       Date:  2009-03       Impact factor: 5.006

4.  Enhanced endotoxin sensitivity in fps/fes-null mice with minimal defects in hematopoietic homeostasis.

Authors:  Ralph A Zirngibl; Yotis Senis; Peter A Greer
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

5.  A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells.

Authors:  H Y Cheng; A P Schiavone; T E Smithgall
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

6.  Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.

Authors:  Sabine Hellwig; Chandra V Miduturu; Shigeru Kanda; Jianming Zhang; Panagis Filippakopoulos; Eidarus Salah; Xianming Deng; Hwan Geun Choi; Wenjun Zhou; Wooyoung Hur; Stefan Knapp; Nathanael S Gray; Thomas E Smithgall
Journal:  Chem Biol       Date:  2012-04-20

7.  Bimolecular fluorescence complementation demonstrates that the c-Fes protein-tyrosine kinase forms constitutive oligomers in living cells.

Authors:  Jonathan M Shaffer; Sabine Hellwig; Thomas E Smithgall
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.